Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2000

View Archived Issues

Columbia concluding phase III study on anti-AIDS spermicide

Private companies cooperate with U.N. on HIV/AIDS treatment access in developing countries

DeveloGen and HepaVec to merge

Orphan drug status granted for Merrem I.V. as cystic fibrosis treatment

Avax begins phase I/II study of L-Vax for treatment of AML

Uniprost to be marketed by Ferrer in Europe and Latin America

Amylin and Alkermes establish agreement for new formulation of AC-2993

Ligand reports data from two trials of Targretin gel formulation in CTCL

Researchers at Ortho-McNeil claim new series of NPY Y5 receptor ligands and use thereof

Primate-specific genotype of hepatitis B suggests new theory for virus pandemic

Inhaled interleukin-2 shows promise as a treatment for lung metastases of malignant melanoma

Glaxo Wellcome reveals recent findings in its thrombin inhibitor program

ADIR describes preparation and use of new cyclic melatonin receptor ligands

Nonpeptide GnRH receptor modulators with improved pharmaceutical properties

Joint research at Japanese labs leads to design of high-affinity MDR ligands

New series of ECE inhibitors in early development by Sumitomo

Conjugates for diagnosis and treatment of tumors prepared at Schering

Japanese patent covers Kanebo's new Na+/H+ exchange inhibitors

Bronchodilating PDE4 inhibitors synthesized and tested by Dainippon

Human MAbs targeting PTHrP useful for bone and calcium metabolism disorders

Drug may provide the basis for a new class of neuropsychiatric medications

Two potent and selective iNOS inhibitors discovered by Glaxo Wellcome

Eryloside F: a new thrombin receptor antagonist produced by a marine sponge

Company Profile: Salpep Biotechnology

Transplant 2000 news: JAK3 inhibitor shows promise for islet transplantation

Company Profile: Axxima Pharmaceuticals

Significant CD3 depletion with minimal cytokine release in patients receiving PDL's HuM291

POH presented at Transplant 2000 as representative of a new class of immunosuppressants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...